Quintiles, the contract research organization, has announced theacquisition of Ungerer Laboratory, including the assets of Bavaria pd CC, which are both based in Pretoria, South Africa. Ungerer, founded in 1998, specializes in microbiology, molecular biology and hematology and has 87 employees. Financial terms of the deal were not disclosed, but Quintiles said that the acquisition should be neutral to its earnings per share in 2001.
Oppel Greeff, Quintiles' president for South Africa and India, said that the capabilities and technology of Ungerer will give the firm greater capacity to coordinate its reference and clinical laboratory activities. He added that "this will be especially valuable in enhancing our ability to provide full product development services in South Africa." In 1999, Quintiles set up a laboratory services partnership in South Africa and acquired a pharmaceutical regulatory consulting group.
......and opens facility in Singapore
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze